Mostrar el registro sencillo del ítem

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCAMBON, Linda
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSCHWARZINGER, Michael
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorALLA, Francois
dc.date.accessioned2022-01-13T09:10:44Z
dc.date.available2022-01-13T09:10:44Z
dc.date.issued2022-01-21
dc.identifier.issn1873-2518 (Electronic) 0264-410X (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/124366
dc.description.abstractEnFrance is one of the most vaccine-hesitant countries in the world, including for coronavirus disease 2019 (COVID-19). After 10 months of restrictive measures and media coverage of the dangers of COVID-19, French attitudes towards a vaccine continue to deteriorate. The communication strategies of the government have not helped; in fact, they have made the situation worse. Empirical studies on the national strategy for management of the COVID-19 pandemic in France have shed light on the reasons for vaccine hesitancy. These studies have identified four pillars for the vaccination strategy: i) Communication regarding the importance of herd immunity, ii) making healthcare workers the focus of the vaccination campaign, iii) citizen mobilization and guaranteed consultations, and iv) access to free vaccines without delay. This paper discusses the evidence supporting this strategy.
dc.description.sponsorshipEtude des leviers permettant de maximiser la vaccination contre la Covid-19 dans la population adulte âgée de 18 à 64 ans à faible risque d'infection sévère - ANR-21-CO16-0006en_US
dc.language.isoENen_US
dc.subject.enModels
dc.subject.enVaccine hesitancy
dc.subject.enFrance
dc.subject.enCovid-19
dc.title.enIncreasing acceptance of a vaccination program for coronavirus disease 2019 in France: A challenge for one of the world's most vaccine-hesitant countries
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.vaccine.2021.11.023en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34863619en_US
bordeaux.journalVaccineen_US
bordeaux.page178-182en_US
bordeaux.volume40en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamPHARES_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAgence Nationale de la Rechercheen_US
hal.identifierhal-03524174
hal.version1
hal.date.transferred2022-01-13T09:10:46Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Vaccine&rft.date=2022-01-21&rft.volume=40&rft.issue=2&rft.spage=178-182&rft.epage=178-182&rft.eissn=1873-2518%20(Electronic)%200264-410X%20(Linking)&rft.issn=1873-2518%20(Electronic)%200264-410X%20(Linking)&rft.au=CAMBON,%20Linda&SCHWARZINGER,%20Michael&ALLA,%20Francois&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem